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Abstract 
 
Translation elongation factor eEF1A exists as two individually-encoded variants in 
mammals which are 98% similar and 92% identical at the amino acid level. One 
variant, eEF1A1, is almost ubiquitously expressed, the other variant, eEF1A2, shows 
a very restricted pattern of expression. A spontaneous mutation was described in 1972 
which gives rise to the wasted phenotype: homozygous wst/wst mice develop 
normally until shortly after weaning, but then lose muscle bulk, acquire tremors and 
gait abnormalities and die by four weeks. This mutation has been shown to be a 
deletion of 15kb that removes the promoter and first exon of the gene encoding 
eEF1A2. The reciprocal pattern of expression of eEF1A1 and eEF1A2 in muscle fits 
well with the timing of onset of the phenotype of wasted mice: eEF1A1 declines after 
birth until it is undetectable by three weeks whereas eEF1A2 expression increases 
over this time. No other gene is present in the wasted deletion, and transgenic studies 
have shown that the phenotype is due to loss of eEF1A2. We have shown that 
eEF1A2, but not eEF1A1, is also expressed at high levels in motor neurons in the 
spinal cord. Wasted mice develop many pathological features of motor neuron 
degeneration and may represent a good model for early onset motor neuron disease. 
Molecular modelling of the eEF1A1 and eEF1A2 protein structures highlights 
differences between the two variants that may be critical for functional differences. 
Interactions between eEF1A2 and ZPR1 may be important in motor neuron biology. 
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eEF1A variants and the wasted mouse mutation 
 
Translation elongation is a tightly controlled, crucial process involving a number of 
elongation factors: eEF1A is responsible for the delivery of aminoacylated tRNAs to 
the A site of the ribosome in a GTP dependent process mediated by the multi subunit 
protein eEF1B; translocation is then facilitated by eEF2. During the last few years 
translation factors have been directly implicated in human disease; mutations in 
subunits of initiation factor eIF2B have been found to be mutated in vanishing white 
matter (1) and elongation factor eEF1A2 has been found to be a potential oncoprotein 
in ovarian cancer and has been shown to be overexpressed in a number of other 
tumour types (2-5).  
 
eEF1A (formerly known as EF1α) is the second most abundant protein in the cell. It 
exists in mammals as two variant forms encoded by separate genes which give rise to 
proteins that are 92% identical and 98% similar but which have different expression 
patterns: eEF1A1 is almost ubiquitously expressed but eEF1A2 is expressed only in 
brain, spinal cord, heart and muscle at the level of detection in whole tissues. 
  
We have shown that a 15 kb deletion abolishing expression of eEF1A2 is responsible 
for the mutant mouse phenotype wasted (6), a model for motor neuron degeneration 
(7). The wasted (wst) mutation of the mouse arose spontaneously in the Jackson Lab 
in 1972 (8). Mice which are homozygous for the mutation develop loss of muscle 
bulk, tremors and gait abnormalities from just after weaning (three weeks of age) and 
then die by four weeks; this timing is unaffected by genetic background or 
environmental changes. At a microscopic level, the only notable changes in the mice 
are seen in the spinal cord; the phenotype of homozygous mice closely resembles that 
of early onset motor neuron disease (MND, also known as amyotrophic lateral 
sclerosis or ALS). Progressive retraction of neurons from motor nerve endplates is 
seen, starting at 17 days at the thoracic level and extending to the lumbrical level by 
23 days. The mice have weak synaptic transmission at 23 days at the thoracic level 
and by 25 days at the lumbrical level, so again there is a progressive deterioration 
with a rostrocaudal gradient. Wasted mice show signs of reactive gliosis and 
perikaryal neurofilament accumulation from 19 days, and conspicuous vacuolation of 
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motor neurons from 25 days. Muscle bulk is lost from 20 days, and wst/wst mice 
perform less well than their normal littermates on rotarod assays from 21 days (9). In 
all, the phenotype of the mice reflects many of the changes seen in human motor 
neuron disease, but with early onset, and compressed into a very short time-frame.  
 
The wasted deletion removes the promoter and first exon of the gene encoding 
eEF1A2 (6). The reciprocal pattern of expression of eEF1A1 and eEF1A2 fits well 
with the timing of onset of the phenotype of wasted mice: eEF1A1 in muscle declines 
after birth until it is undetectable by three weeks whereas eEF1A2 expression 
increases over this time (6,10). No other gene is present in the wasted deletion, and 
our transgenic studies using BAC-mediated correction have shown that the phenotype 
is due to loss of eEF1A2. Mouse BACs, large genomic constructs spanning the gene 
encoding eEF1A2 with several genes on each side, were used to make transgenic 
mice. These were then crossed to +/wst mice and then backcrossed to further +/wst 
mice to generate wst/wst mice carrying the transgene; the phenotype of these mice 
was then compared with non-transgenic wasted mice. BACs spanning the deleted 
region corrected all aspects of the wasted phenotype, but a BAC with a specific 
deletion of exons 2 to 4 of eEF1A2 (i.e. the exons encoding the GTP binding sites) 
failed to correct any aspect of the phenotype (11), showing that the only gene 
implicated in the phenotype is that encoding eEF1A2. We have further shown that 
eEF1A2, but not eEF1A1, is expressed at very high levels in motor neurons in the 
spinal cord (11). This correlates well with the pathology seen in the spinal cords of 
wasted mice, particularly the loss of motor neurons (presumably because these cells 
are no longer capable of carrying out protein synthesis). Using a panel of isoform-
specific antibodies, we have also identified hitherto unsuspected sites of expression of 
eEF1A2 in normal tissue, such as enteroendocrine cells at the base of crypts in the 
intestine, glucagon expressing cells in the pancreatic islets and ganglion cells in the 
retina (11). It is not yet known, however, whether these sites of expression are 
specific to eEF1A2, or whether eEF1A1 is also expressed in these cell types. 
 
Non-canonical functions of eEF1A 
 
In addition to its role in translation, eEF1A1 has been shown to have numerous 
additional non-canonical (or “moonlighting”) functions, ranging from cytoskeletal 
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interactions (12) and apoptosis (13) to a role in proteasomal mediated degradation of 
damaged proteins (14). It has not yet been unequivocally established whether eEF1A2 
shares any or all of these moonlighting functions, although in the case of apoptosis, it 
has been shown that in cultured differentiated myotubes, eEF1A1 is pro-apoptotic 
whereas eEF1A2 is anti-apoptotic (15). There are also many papers which 
demonstrate critical roles for eEF1A in diverse processes but where the precise 
variant is not identified because the only commercially available antibodies for 
eEF1A recognise eEF1A1 and eEF1A2 equally, and because peptides identified in the 
course of proteomics experiments are often from regions that are completely 
conserved between eEF1A1 and eEF1A2 (13). For example, a rapid increase in local 
eEF1A synthesis in response to long term potentiation (LTP) induction has been 
shown, suggesting a role for eEF1A in maintenance of LTP (16), and eEF1A has been 
demonstrated to have a role in mediating the heat shock response (17). A study of 
proteins that interact with a subunit of the inhibitory glycine receptor identified 
eEF1A as an interacting protein, together with other members of the translational 
machinery (18). eEF1A has also recently been shown to be a novel component of the 
nuclear export machinery in mammalian cells (19), and is involved in the nuclear 
export of proteins with a specific motif, including the von Hippel Lindau tumour 
suppressor. In none of these instances is it yet known whether the properties described 
are shared by both isoforms, or whether they are eEF1A1- or even eEF1A2-specific. 
 
The observation that forced expression of eEF1A2 can transform cells and give rise to 
tumours in nude mice (3), when these cells already express eEF1A1 at high levels, 
suggests that there are real functional differences between the two variants. It may be 
that these relate entirely to their role in translation, but it is equally (and arguably 
more) likely that there are differences in non-canonical functions. The cell types that 
switch off eEF1A1 tend to be those that have a strong, stable cytoskeletal 
organisation, such as neurons and muscle; it is an attractive hypothesis that these cell 
types need to switch off eEF1A1 in order to prevent or modify the cytoskeletal 
rearranging properties of eEF1A1, but because of the obvious need to maintain 
protein synthesis they use eEF1A2. It is also noteworthy that muscle cells switch 
eEF1A1 back on in response to denervation or toxic injury, reverting back to high 
levels of eEF1A2 after recovery (20,21). 
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Molecular modelling of eEF1A variants  
 
eEF1A is a GTP-binding protein; the GTP exchange factor necessary for this activity 
is called eEF1B, which is a complex of three subunits, alpha, delta and gamma (22). 
eEF1A1 and eEF1A2 have similar properties in an in vitro translation assay, but in 
spite of the GTP binding sites being conserved, have different affinities for GTP and 
GDP. eEF1A1 has a seven-fold higher GDP dissociation rate than eEF1A2, and the 
GDP/GTP preference ratio is 0.82 for eEF1A1 but 1.5 for eEF1A2 (23); these data 
together suggest that eEF1A2 would have a greater dependence on a GTP exchange 
factor than eEF1A1. It was surprising, then, that yeast 2-hybrid experiments showed 
that whilst eEF1A1 binds all three eEF1B subunits, eEF1A2 showed little or no 
affinity for any of them (24), even though the eEF1A2 “bait” construct was able to 
interact with other proteins (25). This is even more surprising when the two variants 
are subjected to homology modelling (26), and the positions of the non-conserved 
amino acid residues mapped on their surfaces, showing that virtually all the amino 
acid differences between eEF1A1 and eEF1A2 are clustered in two areas of the 
protein, both of which are on the opposite side of the molecules from the eEF1Bα-
binding site (figure 1). This puzzle has yet to be resolved, but it remains a possibility 
that whilst eEF1B is the GTP exchange factor for eEF1A1, eEF1A2 uses a different, 
as yet unidentified, GTP exchange factor. Additionally, the close congregation of 
variable amino acids that are highly conserved among their respective eEF1A1 and 
eEF1A2 orthologues could comprise important binding sites that confer 
altered/different functional properties for the two human variants. 
 
eEF1A, ZPR1 and SMN 
 
It has been known for some years that eEF1A (again, it is unknown whether this is 
eEF1A1, eEF1A2 or both) can be found in a complex with a zinc finger-containing 
transcription factor, ZPR1 (27). ZPR1 is in turn complexed with the survival motor 
neuron protein, SMN; this interaction is essential for the correct localisation of SMN 
in neurons. SMN is mutated in spinal muscular atrophy, an early onset form of motor 
neuron disease (28). It has not been established whether there is any direct contact 
between eEF1A and SMN, but a protein of the same size as eEF1A copurifies with 
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the ZPR1/SMN complex that seems likely to be eEF1A (29). Interestingly, mice that 
are heterozygous for a Zpr1 knockout mutation develop motor neuron disease, with 
motor neurons being progressively lost over a 12 month period (30). The mice show 
mislocalisation of SMN in the motor neurons.  
 
ZPR1 forms complexes preferentially with eEF1A-GDP, and in fact competes with 
the alpha subunit of eEF1B for binding (31). It is possible; therefore, that ZPR1 
preferentially binds eEF1A2 as there is likely to be a consistently greater proportion 
of eEF1A2 in a GDP-bound form, compared to eEF1A1. It would have been an 
attractive hypothesis that ZPR1 was in fact the GTP exchange factor for eEF1A2; 
however, Mishra et al showed that ZPR1 does not modulate the intrinsic nucleotide 
binding kinetics of eEF1A (31). We are now studying aged mice which are 
heterozygous for the wasted mutation (+/wst), to see if they also develop a late-onset 
form of motor neuron disease. It could be that eEF1A2 heterozygotes do not have 
sufficient eEF1A2 to interact with ZPR1 and thus to maintain motor neurons.  
 
 
Conclusions 
 
The discovery that eEF1A exists as two distinct tissue-specific variants (32,33), and 
that the loss of eEF1A2 causes motor neuron degeneration has opened up new fields 
of study. Translation factors have generally been assumed to be ubiquitously 
expressed on the basis of their housekeeping functions, but it is increasingly clear that 
there are levels of complexity in the control of expression of these factors that remain 
to be discovered. The wasted mouse has proved to be a valuable tool in the study of 
eEF1A biology, and may also be a useful model for studying the processes involved 
in motor neuron degeneration. 
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Figure 1: Changes in ventral (anterior) horn neurons of wst/wst mice.  The ventral 
horns of wst/wst (left) and wild-type (wt, right) are identified by squares in the upper 
panels. Higher magnifications of areas within the squares are shown in the lower 
panels. Motor neurons of the wst/wst mice are swollen with multiple cytoplasmic 
vacuoles.  
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Figure 2: Location of eEF1Bα-binding site on yeast eEF1A and variations in 
amino acids between human eEF1A1 and eEF1A2 mapped onto surface.  Two 
equivalent views rotated by 180° about the y-axis depicting: (A) a cartoon schematic 
representation of the yeast crystal structure (34) showing the C-terminal eEF1Bα 
fragment (cyan) bound to eEF1A (green); (B) surface representations of the yeast 
eEF1A crystal structure with the location of the eEF1Bα-binding site (cyan) mapped 
on it; (C) the three-dimensional model of human eEF1A1, and (D) human eEF1A2, 
with locations of surface-exposed variant amino acid side-chains mapped (yellow) 
[Soares et al., submitted].  The two sub-clusters are apparent in this representation, 
located on the opposite side from the known eEF1Bα-binding site (34).   
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